Equities Analysts Issue Forecasts for TVTX FY2030 Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX) – HC Wainwright issued their FY2030 earnings estimates for shares of Travere Therapeutics in a report issued on Wednesday, January 14th. HC Wainwright analyst J. Pantginis forecasts that the company will earn $7.33 per share for the year. HC Wainwright currently has a “Buy” rating and a $47.00 price objective on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($1.40) per share.

Travere Therapeutics (NASDAQ:TVTX) last posted its earnings results on Thursday, October 30th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of ($0.31) by $0.59. The firm had revenue of $164.86 million for the quarter, compared to analyst estimates of $106.09 million. Travere Therapeutics had a negative return on equity of 178.68% and a negative net margin of 20.32%.Travere Therapeutics’s revenue for the quarter was up 162.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.70) earnings per share.

TVTX has been the subject of several other reports. TD Cowen raised their price target on Travere Therapeutics from $30.00 to $40.00 and gave the company a “buy” rating in a report on Friday, October 31st. Guggenheim reiterated a “buy” rating and set a $49.00 target price on shares of Travere Therapeutics in a report on Wednesday. Cowen restated a “buy” rating on shares of Travere Therapeutics in a research report on Friday, October 31st. Wall Street Zen upgraded Travere Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 13th. Finally, Zacks Research downgraded Travere Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 12th. Thirteen analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Travere Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $38.86.

Travere Therapeutics Stock Down 1.5%

Shares of Travere Therapeutics stock opened at $28.49 on Thursday. The company has a market cap of $2.55 billion, a P/E ratio of -27.23, a PEG ratio of 1.03 and a beta of 0.85. The firm has a fifty day moving average of $35.52 and a two-hundred day moving average of $26.29. The company has a debt-to-equity ratio of 4.23, a quick ratio of 2.71 and a current ratio of 2.75. Travere Therapeutics has a one year low of $12.91 and a one year high of $42.13.

Institutional Trading of Travere Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Capital Fund Management S.A. bought a new position in Travere Therapeutics in the 2nd quarter worth $1,501,000. Squarepoint Ops LLC grew its holdings in Travere Therapeutics by 98.7% during the 2nd quarter. Squarepoint Ops LLC now owns 479,394 shares of the company’s stock worth $7,095,000 after acquiring an additional 238,070 shares during the last quarter. Voya Investment Management LLC raised its stake in shares of Travere Therapeutics by 16.2% in the third quarter. Voya Investment Management LLC now owns 194,854 shares of the company’s stock worth $4,657,000 after acquiring an additional 27,133 shares during the last quarter. Y Intercept Hong Kong Ltd increased its stake in shares of Travere Therapeutics by 343.7% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 68,000 shares of the company’s stock valued at $1,006,000 after buying an additional 52,675 shares during the period. Finally, Hussman Strategic Advisors Inc. bought a new stake in shares of Travere Therapeutics during the second quarter worth approximately $2,486,000.

Insider Activity

In other Travere Therapeutics news, CFO Christopher R. Cline sold 20,000 shares of the firm’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $35.01, for a total value of $700,200.00. Following the transaction, the chief financial officer directly owned 92,083 shares of the company’s stock, valued at $3,223,825.83. This trade represents a 17.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider William E. Rote sold 60,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 24th. The shares were sold at an average price of $40.10, for a total value of $2,406,000.00. Following the completion of the sale, the insider owned 101,443 shares of the company’s stock, valued at $4,067,864.30. This trade represents a 37.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 323,226 shares of company stock worth $11,290,656 in the last quarter. Insiders own 4.19% of the company’s stock.

About Travere Therapeutics

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.